The role of EZH2 and DNA methylation in hMLH1 silencing in epithelial ovarian cancer

Biochemical and Biophysical Research Communications

Volumn 433, Issue 4, 2013, Pages 470-476

  Wang, Junjie ^a   Yu, Lili ^a   Cai, Jing ^a   Jia, Jinghui ^a   Gao, Yanping ^b   Liang, Minglin ^a   Wang, Zehua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b The First Hospital of Datong   (China)

Author keywords

Epigenetics; EZH2; HMLH1; Methylation; Ovarian cancer

Indexed keywords

DNA; PROTEIN MLH1; RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPITHELIUM OVARIAN CANCER; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MODULATION; OVARY CANCER; PRIORITY JOURNAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; BLOTTING, WESTERN; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84876473022     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.03.037     Document Type: Article

References (29)

1. Cao R., Wang L., Wang H., Xia L., Erdjument-Bromage H., Tempst P., Jones R.S., Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002, 298:1039-1043.
2. Matsukawa Y., Semba S., Kato H., Ito A., Yanagihara K., Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 2006, 97:484-491.
3. Bryant R.J., Cross N.A., Eaton C.L., Hamdy F.C., Cunliffe V.T. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007, 67:547-556.
4. Collett K., Eide G.E., Arnes J., Stefansson I.M., Eide J., Braaten A., Aas T., Otte A.P., Akslen L.A. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin. Cancer Res. 2006, 12:1168-1174.
5. Guo J., Cai J., Yu L., Tang H., Chen C., Wang Z. EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci. 2011, 102:530-539.
6. Hu S., Yu L., Li Z., Shen Y., Wang J., Cai J., Xiao L., Wang Z. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol. Ther. 2010, 10:788-795.
7. Thibodeau S.N., Bren G., Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993, 260:816-819.
8. Murphy M.A., Wentzensen N. Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America. Int. J. Cancer 2011, 129:1914-1922.
9. Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., Lescoe M.K., Kane M., Earabino C., Lipford J., Lindblom A., et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994, 368:258-261.
10. Papadopoulos N., Nicolaides N.C., Wei Y.F., Ruben S.M., Carter K.C., Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., Adams M.D., et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994, 263:1625-1629.
11. Geisler J.P., Goodheart M.J., Sood A.K., Holmes R.J., Hatterman-Zogg M.A., Buller R.E. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 2003, 98:2199-2206.
12. Gras E., Catasus L., Arguelles R., Moreno-Bueno G., Palacios J., Gamallo C., Matias-Guiu X., Prat J. Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 2001, 92:2829-2836.
13. Vikhanskaya F., Colella G., Valenti M., Parodi S., D'Incalci M., Broggini M. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage. Clin. Cancer Res. 1999, 5:937-941.
14. Strathdee G., Appleton K., Illand M., Millan D.W., Sargent J., Paul J., Brown R. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol. 2001, 158:1121-1127.
15. Wiley A., Katsaros D., Chen H., Rigault de la Longrais I.A., Beeghly A., Puopolo M., Singal R., Zhang Y., Amoako A., Zelterman D., Yu H. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006, 107:299-308.
16. Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., Christen R.D., Boland C.R., Koi M., Fishel R., Howell S.B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996, 56:3087-3090.
17. Plumb J.A., Strathdee G., Sludden J., Kaye S.B., Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000, 60:6039-6044.
18. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.M., Bollen M., Esteller M., Di Croce L., de Launoit Y., Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
19. Rush M., Appanah R., Lee S., Lam L.L., Goyal P., Lorincz M.C. Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation. Epigenetics 2009, 4:404-414.
20. McGarvey K.M., Fahrner J.A., Greene E., Martens J., Jenuwein T., Baylin S.B. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res. 2006, 66:3541-3549.
21. Colella G., Vikhanskaya F., Codegoni A.M., Bonazzi C., D'Incalci M., Broggini M. HMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors. Carcinogenesis 1998, 19:691-694.
22. Swisher E.M., Gonzalez R.M., Taniguchi T., Garcia R.L., Walsh T., Goff B.A., Welcsh P. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol. Cancer 2009, 8:48.
23. Strathdee G., MacKean M.J., Illand M., Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999, 18:2335-2341.
24. McGarvey K.M., Greene E., Fahrner J.A., Jenuwein T., Baylin S.B. DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2. Cancer Res. 2007, 67:5097-5102.
25. Kondo Y., Shen L., Cheng A.S., Ahmed S., Boumber Y., Charo C., Yamochi T., Urano T., Furukawa K., Kwabi-Addo B., Gold D.L., Sekido Y., Huang T.H., Issa J.P. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 2008, 40:741-750.
26. Gonzalez M.E., DuPrie M.L., Krueger H., Merajver S.D., Ventura A.C., Toy K.A., Kleer C.G. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res. 2011, 71:2360-2370.
27. Bonasio R., Tu S., Reinberg D. Molecular signals of epigenetic states. Science 2010, 330:612-616.
28. Tsai M.C., Manor O., Wan Y., Mosammaparast N., Wang J.K., Lan F., Shi Y., Segal E., Chang H.Y. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010, 329:689-693.
29. Au S.L., Wong C.C., Lee J.M., Fan D.N., Tsang F.H., Ng I.O., Wong C.M. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 2012, 56:622-631.